Pharmacotherapeutic management of chronic viral hepatitis

Gabriela Mitea, Marius Daniel Radu, Ana Maria Ionescu and Nicoleta Blebea
Additional contact information
Gabriela Mitea: Ovidius University of Constanta, Faculty of Pharmacy, Constanta, Romania
Marius Daniel Radu: Ovidius University of Constanta, Faculty of Natural and Agricultural Sciences, Constanta, Romania
Ana Maria Ionescu: Ovidius University of Constanta, Faculty of Medicine, Constanta, Romania
Nicoleta Blebea: Ovidius University of Constanta, Faculty of Pharmacy, Constanta, Romania

Technium BioChemMed: Journal of Multidisciplinary Research, Biology, Chemistry and Medicine ISSN 2734 - 7990, 2021, vol. 2, issue 4, 1-8

Abstract: In infectious diseases, viral hepatitis has an increased incidence, being an important cause of morbidity and mortality, being a "sentinel" indicator of the socio-economic and hygienic-cultural standard of a geographical area. The World Health Organization (WHO) admits the following types of hepatitis viruses: A, B, B + D, C, E, F and G. Among the viral entities recognized by the WHO, a special importance in terms of incidence, evolution over time with the risk of chronicity and the therapeutic options are presented by hepatitis B and C. There is currently an effective vaccine as well as treatment for hepatitis B. There is no vaccine for hepatitis C, but in recent years considerable progress has been made in treating this disease. Also, the introduction of drugs known as direct-acting antivirals makes it possible to cure over 90% of patients within 2-3 months. But in many countries, current drug policies, regulations and prices keep treatment out of the reach of most people with hepatitis. Eradication of viral hepatitis is possible if greater emphasis is placed on prevention, diagnosis and treatment. Vaccination is very important, as it is possible for types A and B of hepatitis. Early diagnosis is also extremely important, given that there are currently very effective drugs that can prevent the development of liver cancer. The WHO also noted that about two million people worldwide become ill each year due to the reuse of syringes and stressed the importance of checking blood donors to see if they are not carriers of hepatitis B or C viruses. Therefore, the purpose of this article is to highlight the pharmacological treatment and the main therapeutic and prevention schemes currently used for patients with these liver diseases. The paper was based on the most popular methods of identification of the latest international information about the treatment of hepatitis (by electronic search using Pubmed, SciFinder, Scirus, GoogleScholar and Web of Science). We also consulted the global literature cited in the hepatitis database of the World Health Organization (WHO) updated frequent from the current literature on this topic.

Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://techniumscience.com/index.php/biochemmed/article/view/4627 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:tec:bioche:ojs:4627

DOI: 10.47577/biochemmed.v2i4.4627

Access Statistics for this article

Technium BioChemMed: Journal of Multidisciplinary Research, Biology, Chemistry and Medicine ISSN 2734 - 7990 is currently edited by Anna Maria Golita

More articles in Technium BioChemMed: Journal of Multidisciplinary Research, Biology, Chemistry and Medicine ISSN 2734 - 7990 from Technium Science
Bibliographic data for series maintained by Anna Maria Golita ().